• Serina Therapeutics’ third-quarter 2026 net loss attributable to common stockholders widened 68% year over year to $7.9 million.
• Operating expenses rose 25% to $8 million, while research and development spending climbed 28% to $4.6 million year over year.
• Cash and cash equivalents totaled $19.4 million at September 30, 2026.
• Dosing began in Cohort 2 of the SER-252 Parkinson’s disease study following an independent safety committee’s recommendation to advance.
• Topline data from the study’s single-ascending-dose portion are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000069), on November 12, 2026, and is solely responsible for the information contained therein.